Introduction
Tumor invasion is thought to involve adhesive interactions between tumor cells and the host extracellular matrix (1, 2) . Thus, one approach to understanding tumor cell invasion is to identify the matrix proteins and their receptors within the tumor parenchyma. Glioblastoma multiforme (GBM),' the highest grade astroglial-derived tumor, grows in an adhesive manner in culture (3) within these tumors. GBM tumors are derived from glial cells, and in normal adult brain these cells and the surrounding extracellular matrix (neuropil) are devoid ofmost, ifnot all, previously characterized extracellular matrix adhesive proteins (4) (5) (6) (7) (8) .
In an effort to understand the adhesive interactions within GBM tumors, we examined GBM cryostat sections for the expression of a variety of extracellular matrix adhesive proteins. Among the proteins examined, within the parenchyma of GBM tumors, only vitronectin was detected. Vitronectin is an adhesive protein normally found in plasma, and has been shown to promote the adhesion ofa wide variety ofcell types in vitro (9) (10) (11) (12) (13) . Vitronectin has been identified in the embryonic chick retina, where it serves to promote neurite extension (14) ; however, in the adult mammal no adhesive function for vitronectin in situ has been identified. Vitronectin has several other functional domains, such as the collagen-and heparin-binding domains (13) , that are likely involved in the in situ localization of vitronectin to reactive connective tissue (15) (16) (17) (18) (19) (20) . In this location, vitronectin is thought to be derived from serum.
In this study we examined the adhesive interactions within GBM tumors and found the functional expression of vitronectin and the vitronectin receptor integrin avB3 associated with the GBM tumor cell surface. Cultured GBM tumor cells specifically attached to cryostat sections of GBM tumors at sites containing vitronectin, and this adhesion event was inhibited by antibodies directed to vitronectin or the integrin avi33. These data provide evidence for a cell adhesion mechanism in GBM tumors that may facilitate glioblastoma cell invasion ofnormal brain. Methods
Reagents. BSA, glucose, Tris base, NaCl, KCI, monovalent and divalent sodium phosphate, and methylene blue were purchased from Sigma Chemical Co. (St. Louis, MO). SDS Subsequently, the slide containing a 70-mm2 cryostat serial GBM tumor section was flooded with 50,000 cells (U25 1) in 0.2 ml adhesion buffer (10 min, room temperature). The slide was flooded with the tumor cell suspension to ensure the tissue section was uniformly covered with cells. Sections of GBM tumor free of necrosis and hemorrhage, were used in this assay. After attachment, the slides were washed 3 times in agitated PBS (1 min/wash), postfixed in 3% paraformaldehyde, washed with 0.1 M glycine/PBS followed by PBS, dehydrated with 100% ethanol, and coverslipped. Alternatively, some sections were stained in 1% methylene blue before dehydration and coverslipping. Adhesion was allowed to take place in the presence of antibodies or controls as indicated in the figure legends. The time course of adhesion (10 min) was specifically chosen to examine the initial events of U25 1 cell attachment to GBM tissue. Longer incubation, 15-60 min, produced significant cell spreading on these cryostat sections. The 10-min incubation was chosen because the multiple molecular events involved in cell spreading on intact tissues for longer times would be difficult to interpret. After adhesion, washing, and fixation, the number ofcells attached on each section were counted blindly using an inverted microscope with phase optics. In a typical experiment, in the absence of inhibitor (antibody or peptide), 300-350 cells were counted per (70-mm2) section. The cells attached to regions of the tumor expressing vitronectin. Based on the number of cells (50,000) per total slide area (1,000 mm2), and the 70-mm2 area ofthe tumor section, -10% ofthe cells available to the tissue section attached. This is likely a low estimate, assuming vitronectin is the predominant ligand the U25 1 cells are adhering to in the tumor section, and 30% of the tumor section expressed vitronectin.
Results
To determine what matrix proteins were expressed on GBM tumors, serial cryostat sections were allowed to react with antibodies directed to vitronectin, fibrinogen, thrombospondin, fibronectin, von Willebrand factor, tenascin, laminin, and collagen type IV. Reactivity of these antibodies was detected by indirect immunoperoxidase staining, as described in Methods.
As shown in Table I Fig. 2 D) . Adult glial-derived tumors arise predominantly in the cerebral white matter (21) . To confirm the vitronectin reactivity, the anti-VN antibody was preincubated with purified soluble vitronectin or fibronectin and then reacted with serial GBM cryostat sections. As shown in Fig. 1 (B and D), the staining with anti-VN was completely blocked by purified vitronectin; however, fibronectin failed to effect anti-VN staining (Fig. 1 , A and C). As previously described in untreated GBM tumors, fibronectin (4-6), laminin (6, 7), collagen types I, III, IV, V, and VI (5, 6), and von Willebrand factor (8) were specifically localized to the endothelial cell basement membrane and or pial/glial basement membrane, and were not found to be tumor cell associated. In this study, tenascin was restricted to the endothelial and pial/glial basement membranes; however, other studies (23) 
Cryostat sections of normal adult cortex and cerebral white matter were reacted with antibodies to the following antigens by the immunoperoxidase technique, as described in Methods. these results indicate that among a wide variety of potential matrix components, vitronectin appears to be a major adhesive ligand in GBM tumor parenchyma (5/5). Vitronectin staining ofGBM tissue was associated with the tumor cell membrane and/or cytoplasm ( Fig. 2 A, arrows) , while the adjacent vessels were predominantly nonreactive, as detected by the anti-VN MAb 8E6 (Fig. 2 A, arrowheads) . This suggested that the GBM tumor cell membrane vitronectin was not derived from capillary leakage. In contrast, fibronectin staining was restricted to the blood vessels as observed in a serial section of this tumor (Fig. 2 B) , or those found in the normal brain (Fig. 2 E) . These results suggest that the vitronectin present in these tissues is tumor cell derived.
We examined earlier-stage astroglial tumors to determine whether vitronectin expression was related to progression of disease. To this end, vitronectin was only detected in malignant astroglial-derived tumors, i.e., GBM tumors (grade IV) (5/5 positive) and anaplastic astrocytomas (grade III) (2/5 positive), while lower grade astrocytomas failed to react with anti-VN (grades I and II) (0/4). Moreover, we could not detect vitronectin associated with glial or neuronal cells in normal adult cortex or cerebral white matter (0/5) (Fig. 2 D) , or in reactive (nontumorous or benign astrocytic proliferation) astrogliosis (0/4). In addition, vitronectin was not detected in an adult cerebral white matter well-differentiated oligodendroglioma (0/1), a glial-derived tumor with a longer survival (21) . This tumor was not included in the total numbers (Table II) , since all other gliomas demonstrated clear predominant astrocytic differentiation. Vitronectin was focally detected in the endothelial cell extracellular matrix or basement membrane oflow grade astrocytomas, as well as higher grade astroglial tumors, and in reactive astrogliosis, consistent with alteration of the blood brain barrier leading to leakage from serum. These results suggest that vitronectin may be a marker of the malignant astroglial cell and its expression correlates with tumor progression. In contrast, both the tumor, normal brain, and reactive astroglial cells reacted with anti-GFAP, a specific marker of glial intermediate filaments (4). In addition, normal brain neuropil or neuronal cell processes reacted with anti-MAP5, while normal rabbit serum (NRS) or NRS IgG failed to react with the tumors or normal adult cortex and cerebral white matter.
To determine whether vitronectin could be localized to other tumor cells in situ, we examined a variety ofother tumors for expression ofthis adhesive protein. Vitronectin was specifically detected as tumor cell associated in metastatic melanoma (2/2), a primary leptomeningeal melanoma, and a seminoma with embryonal cell carcinoma. However, we were unable to detect vitronectin in association with tumor cells in renal cell carcinoma or late-stage (invasive) breast, lung, and colon adenocarcinomas. It was present, however, in the perivascular connective tissue in these tumors, as previously described for breast and colon adenocarcinomas (24) . Taken together, these data indicate that vitronectin expression is associated with malignant cells ofneuroectodermal (glioblastoma and melanoma) and germ cell line derivation.
To assess whether GBM tumors express a receptor capable of recognizing vitronectin within the tumor parenchyma, we investigated whether these tumors expressed one or both ofthe two known nonplatelet vitronectin receptors (VNR), integrin av#3 or av35 (9) (10) (11) (12) . Serial GBM cryostat sections were allowed to react with antibodies directed to integrin av, (33, and (35 subunits. As shown in Fig. 2 C, a MAb directed against av (10) reacted throughout the tumor, primarily with the tumor cell membrane. Similar but focal staining was observed with MAb AP3, directed to the integrin (33 subunit (25) , consistent with the presence of the av(33 VNR in these tumors. In four GBM tumors examined with serial sections, the MAb AP3 and antivitronectin staining colocalized. In contrast, a polyclonal antibody directed to the (35 subunit (26) (Table II) . Therefore, av(33, like vitronectin, may be a marker ofmalignant astroglial tumors. Endothelial cells in the GBM tumor (Fig. 2 C) and in normal white matter (Fig. 2  F) expressed the integrin avf33, consistent with the identification of this receptor on endothelial cells in culture (27) .
To determine whether cultured glioblastoma cells express the integrin av(33, U251 glioblastoma cells (3) were surface labeled with '25I and subjected to immunoprecipitation (IP) with antibodies directed to av(33, av, (3, and (31 integrin subunits, as previously described (10) (11) (12) . As shown in Fig. 3 , two A, B, C, and D, respectively. This is consistent with the Mr of the av(33 integrin previously described on melanoma and endothelial cells (10, 27) . Therefore, glioblastoma cells in situ and in culture express av(33. Consistent with a previous study (28) , these cells express (31 integrins (Fig. 3 , lane E).
To determine whether vitronectin might serve an adhesive role in glioblastoma tumors in situ, we examined the ability of U25 1 GBM cells to attach to cryostat sections of GBM tumor tissue. Cryostat sections were chosen to colocalize the GBM vitronectin expression with the U25 1 cell adhesion, as antivitronectin antibodies react weakly or fail to react with formalinfixed tissue. U25 1 glioblastoma cells readily attached to GBM cryostat sections, and 95% of this attachment was in regions expressing vitronectin. This U251 cell attachment to GBM cryostat sections was quantitated in a GBM tumor where 30% ofthe tumor cells expressed vitronectin, as determined by serial section immunoreactivity with the anti-VN MAb 8E6 (Fig. 4,  A and B) . Of the attached U251 cells, 95% localized to the glioblastoma tumor parenchyma where vitronectin was expressed and 5% localized to the blood vessels. In a typical adhesion experiment 300-350 U25 1 cells attached/70 mm2 cryostat section and, as stated in Methods, -10% of available cells attached to the cryostat section. U25 1 cells failed to attach to normal adult neocortex or cerebral white matter. These results suggest that vitronectin expressed in GBM tumors may serve as a relevant adhesive ligand.
To test this hypothesis, U25 1 cells were allowed to attach to GBM cryostat sections that were preincubated with anti-VN. As shown in Fig. 5 , rabbit anti-VN sera blocked this adhesion by -50%. These results suggest vitronectin is among the relevant adhesive ligands present in GBM tumors in situ. In addition, U25 1 cell adhesion to these tissues could be inhibited by 60% with a soluble RGD-containing peptide (GRGDSP) as compared to a random peptide (GDRGSP) (Fig. 5) , consistent with the possibility of this being an RGD-dependent integrinmediated adhesion event.
To determine whether integrin av(33 expressed on U251 cells was involved in this adhesion event, U251 cells were preincubated with rabbit anti-avB3 IgG or MAb anti-av(3 (LM609), and then allowed to attach to the GBM cryostat sections. As shown in Fig. 5 , these antibodies inhibited U25 1 cell attachment to GBM cryostat sections by 70%. A similar inhibition (70-90%) was observed with these antibodies when U251 cells were allowed to attach to microtiter wells coated with purified vitronectin (not shown). In contrast, rabbit antiaS(3l, NRS, and NRS IgG failed to inhibit U25 1 cell adhesion to GBM tumor tissue (Fig. 5) , while anti-aS(l blocked attachment of these cells to purified fibronectin (not shown). These results provide evidence that the vitronectin expressed in GBM tumors may serve an adhesive role in the malignant phenotype of astroglial-derived cells, and that integrin avB3 expressed on the tumor cell surface potentiates this interaction.
Discussion
Adhesive interactions are involved in a diverse array ofbiological processes, including embryogenesis, thrombosis, wound healing, and tumor cell invasion (1, 2). Many ofthese adhesive events are mediated by members of the integrin family of cell adhesion receptors that recognize ligands present in the extracellular matrix or on opposing cells (1, 2) . In fact, tumor cells typically synthesize their own matrix components (29) , and show altered integrin expression (1, 2, 30, 31) as compared to their normal cell counterparts. These observations suggest that tumor cells can remodel their surrounding extracellular matrix to facilitate their invasive phenotype.
In this report, we demonstrate that the adhesive protein vitronectin is found within the parenchyma of late-stage astroglial-derived tumor tissue. Vitronectin may be one of the primary adhesive ligands in these tissues due to the fact that we were unable to detect, as tumor cell associated, a wide variety of other extracellular matrix components including, collagen, fibronectin, fibrinogen, thrombospondin, von Willebrand factor, tenascin, and laminin. In addition, the expression of vitronectin in these tumors may be related to the progression of disease because it could not be detected on low grade astroglialderived tumors, reactive astrogliosis, or on glial cells in the normal adult brain. The vitronectin detected in GBM tumors localizes to the tumor cell cytoplasm and plasma membrane. Thus, unlike fibronectin and other plasma proteins, its expression is independent of blood vessels. These results suggest that the vitronectin present in these tissues is derived from the tumor cells. However, long term cultured cell lines failed to synthesize detectable levels of vitronectin suggesting that, upon culture, cells may lose this property. This may not be surprising because most GBM cell lines (80%) also fail to express GFAP, an intermediate filament and a characteristic marker of glialderived cells and their tumors in situ (3, 4) .
The expression of vitronectin is not restricted to GBM tumors because it was also shown to be tumor cell associated in melanoma and embryonal cell carcinoma. However, vitronectin was not expressed in carcinoma of the breast, colon, lung, and kidney. It is important to point out that, consistent with (32, 33) . Vitronectin is also known to bind the C5-9 membrane attack complex ofcomplement, and thus may prevent complement-mediated cytolysis by host immune cells (19, 20) . Recently, vitronectin was shown to interact with fi-endorphin (34), and the latter was independently demonstrated to bind to the surface of glioblastoma cells (35) , suggesting that vitronectin associated with these tumors may serve to enhance the binding of ,-endorphin.
In summary, this report provides the first evidence that vitronectin is specifically localized to tumor cells in situ. Its expression appears to correlate with the late stages or the most malignant astroglial-derived tumors. Although vitronectin has a number of biological properties, it is capable of serving an adhesive role when expressed in the parenchyma of GBM tumors. The conspicuous absence of other adhesive ligands in normal brain tissue, excluding blood vessels, suggests that the vitronectin present in GBM tumors may facilitate their malignant behavior.
